An Observational, Prospective Analysis of Retreatment With Bortezomib for Multiple Myeloma.
Phase of Trial: Phase IV
Latest Information Update: 07 Mar 2013
At a glance
- Drugs Bortezomib (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Sponsors Janssen
- 10 Dec 2010 Planned end date changed from 1 Nov 2010 to 1 Sep 2010 as reported by ClinicalTrials.gov.
- 10 Dec 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 28 Oct 2010 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.